Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 914-920

  Eskelund, Christian W ^a   Nederby, Line ^a,b   Thysen, Anna H ^a   Skovbo, Anni ^a   Roug, Anne S ^b   Hokland, Marianne E ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

B cell chronic lymphocytic leukaemia; Cancer immunology; IL 21; Immunotherapy; NK cells; Rituximab

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 21; RITUXIMAB;

ADULT; AGED; ARTICLE; CELL STIMULATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOMA CELL LINE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKINS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED;

EID: 79958738879     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.02.006     Document Type: Article

References (33)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
2. Morra E., Nosari A., Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 1999, 41:145-151.
3. Zent C.S., Kyasa M.J., Evans R., Schichman S.A. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001, 92:1325-1330.
4. Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
5. Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91:1644-1652.
6. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
7. Mavromatis B., Cheson B.D. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 2003, 21:1874-1881.
8. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640.
9. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97:3146-3151.
10. Nagler A., Lanier L.L., Phillips J.H. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med 1990, 171:1527-1533.
11. Ziegler S.F., Ramsdell F., Alderson M.R. The activation antigen CD69. Stem Cells 1994, 12:456-465.
12. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
13. Moretta A., Marcenaro E., Parolini S., Ferlazzo G., Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008, 15:226-233.
14. Colucci F., Schweighoffer E., Tomasello E., Turner M., Ortaldo J.R., Vivier E., et al. Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases. Nat Immunol 2002, 3:288-294.
15. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004, 64:4664-4669.
16. Sturm I., Bosanquet A.G., Hermann S., Guner D., Dorken B., Daniel P.T. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003, 10:477-484.
17. Guven H., Gilljam M., Chambers B.J., Ljunggren H.G., Christensson B., Kimby E., et al. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia 2003, 17:1973-1980.
18. Kay N.E., Zarling J. Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. Am J Hematol 1987, 24:161-167.
19. Ziegler H.W., Kay N.E., Zarling J.M. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981, 27:321-327.
20. Palmer S., Hanson C.A., Zent C.S., Porrata L.F., Laplant B., Geyer S.M., et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008, 141:607-614.
21. Thompson J.A., Curti B.D., Redman B.G., Bhatia S., Weber J.S., Agarwala S.S., et al. Study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008, 26:2034-2039.
22. Gowda A., Roda J., Hussain S.R., Ramanunni A., Joshi T., Schmidt S., et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008, 111:4723-4730.
23. Brady J., Hayakawa Y., Smyth M.J., Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004, 172:2048-2058.
24. Roda J.M., Parihar R., Lehman A., Mani A., Tridandapani S., Carson W.E. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006, 177:120-129.
25. Strengell M., Matikainen S., Siren J., Lehtonen A., Foster D., Julkunen I., et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003, 170:5464-5469.
26. Klein E., Klein G., Nadkarni J.S., Nadkarni J.J., Wigzell H., Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 1968, 28:1300-1310.
27. Bryant J., Day R., Whiteside T.L., Herberman R.B. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 1992, 146:91-103.
28. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989, 170:827-845.
29. Lundin J., Porwit-MacDonald A., Rossmann E.D., Karlsson C., Edman P., Rezvany M.R., et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004, 18:484-490.
30. Buggins A.G., Patten P.E., Richards J., Thomas N.S., Mufti G.J., Devereux S. Tumor-derived IL-6 may contribute to the immunological defect in CLL. Leukemia 2008, 22:1084-1087.
31. Rosenberg S.A., Yang J.C., White D.E., Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998, 228:307-319.
32. Atkins M.B., Kunkel L., Sznol M., Rosenberg S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000, 6(Suppl. 1):S11-S14.
33. Timmerman J.M., Byrd J.C., Andorsky D.J., Siadak M.F., DeVries T.A., Hausman D.F., et al. Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma. J Clin Oncol 2008.